同种异体人工血管在胰腺手术静脉间置中的应用:易获得且可靠
该研究基于2003至2022年单中心胰腺切除登记数据,分析201例接受肠系膜门静脉间置移植的择期胰腺切除术患者,其中180例使用人工血管(83%为PTFE,17%为PET)。结果显示人工血管在7、30、90天的通畅率分别为99%、93%、87%,且优于其他材料(HR 2.7,P=0.009),PTFE一年通畅率达78%,90天全因死亡率为10%,无移植物感染发生。
要点
- 人工血管用于肠系膜门静脉间置安全且易获得,尤其适用于长段静脉重建。
- 人工血管通畅率优于其他材料(HR 2.7,P=0.009),PTFE一年通畅率78%。
- 90天全因死亡率为10%,无移植物感染发生。
核心结论
- 人工静脉血管移植物在胰腺手术中是安全且易获得的工具,尤其适用于长段肠系膜门静脉重建。
研究设计与样本
- 回顾性队列研究,纳入2003至2022年单中心胰腺切除登记中接受肠系膜门静脉间置移植(ISGPS 4型)的择期胰腺切除术患者201例,其中23%同时行动脉切除。
主要发现
- 所有移植材料在7、30、90天的通畅率分别为99%、93%、87%。
- 人工血管通畅率优于其他材料(风险比2.7,P=0.009),PTFE一年通畅率达78%。
- 90天全因死亡率为10%,未发生移植物感染。
关键数值与推荐
- 人工血管包括PTFE(83%)和PET(17%),中位直径10 mm,中位长度33 mm(CT测量)。
临床怎么用
- 在胰腺手术需行肠系膜门静脉间置时,可优先考虑人工血管,尤其长段重建,因其易获得且通畅率良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate patency and clinical outcomes of alloplastic and other venous interposition graft materials in pancreatic surgery. BACKGROUND: Vascular pancreatic surgery is increasingly performed for locally advanced pancreatic neoplasms. Different than other centers, we prefer to use alloplastic vascular graft materials for superior mesenteric vein and portal vein interposition in pancreatic surgery. Advantages are off-the-shelf availability at any customizable length, different diameters, and ring-enforcement but proposed concerns are their thrombogenicity and fatal complications. METHODS: Patients who underwent elective pancreatic resections with mesoportal venous interposition grafts (ISGPS type 4) between 2003 and 2022 were identified from the institutional pancreatectomy registry. Alloplastic vascular grafts imply synthetic materials, either based on polytetrafluorethylene (PTFE) or polyethylene terephthalate (PET). Surgical, clinicopathological, and follow-up data were analyzed. The patients were followed for graft patency by cross-sectional imaging. RESULTS: In this study, 201 patients with venous interposition grafts were included (23% simultaneous arterial resections). Total pancreatectomy (41%) and pancreatoduodenectomy (35%) were the most frequent procedures. Vascular graft materials were alloplastic in 180 patients (83% PTFE and 17% PET) with a median diameter of 10 mm and a median length of 33 mm (measurement by computed tomography scan). Patency rates among all graft materials at 7, 30, and 90 days were 99%, 93%, and 87%, respectively. Alloplastic grafts demonstrated superior patency over other materials (hazard ratio: 2.7, P = 0.009), and PTFE reached a 1-year patency of 78%. The all-cause 90-day mortality rate was 10%. No graft infection occurred. CONCLUSIONS: Alloplastic venous vascular grafts are safe and readily available tools in pancreatic surgery, especially for long-segmental mesoportal venous reconstructions.
引用
- Kinny-Köster B, Lambrecht A, Flossmann V, et al. Alloplastic Vascular Grafts for Venous Interposition in Pancreatic Surgery: Readily Available and Reliable. Ann Surg. 2024. PMID: 39508111. doi:10.1097/SLA.0000000000006581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。